{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:29Z","timestamp":1784998949265,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel, accessible treatment options, are needed for patients with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL). Mosunetuzumab, a T-cell\u2013engaging bispecific antibody, plus polatuzumab vedotin, an antibody\u2013drug conjugate, (Mosun-Pola), represents a novel fixed-duration outpatient therapy. The phase III SUNMO study (NCT05171647) demonstrated superior efficacy of Mosun-Pola versus rituximab plus gemcitabine-oxaliplatin (R-GemOx) in patients with R\/R LBCL, with a manageable safety profile. We report outcomes of a Japan subgroup analysis of the SUNMO study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 2:1 to receive Mosun-Pola or R-GemOx. Dual primary endpoints were centrally assessed overall response rate and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At data cutoff (February 17, 2025), of 208 patients randomized (Mosun-Pola,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009138; R-GemOx,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200970), 16 were enrolled from Japan (Mosun-Pola,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; R-GemOx,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). All patients receiving Mosun-Pola achieved a response (100% [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099]) versus 57.1% (n\u2009=\u20094\/7) for those receiving R-GemOx. PFS was significantly prolonged with Mosun-Pola; median PFS of 16.2\u00a0months versus 3.8\u00a0months with R-GemOx (hazard ratio: 0.42; 95% confidence interval: 0.07\u20132.63). In the safety-evaluable population (Mosun-Pola,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; R-GemOx,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097), overall incidence of adverse events was similar between the Japan subgroup and the overall population across both treatment arms. Cytokine release syndrome occurred in 5 patients who received Mosun-Pola; all events were grade 1, and all resolved. No incidence of immune effector cell-associated neurotoxicity syndrome was reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mosun-Pola demonstrated promising efficacy and manageable safety in patients with R\/R LBCL enrolled from Japan, which was comparable with the overall population, supporting Mosun-Pola as a potential new treatment option in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT05171647.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03042-x","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:03:21Z","timestamp":1781543001000},"page":"1547-1556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed\/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial"],"prefix":"10.1007","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct05171647","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"4","key":"3042_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T et al (2014) Difference in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536\u2013545. https:\/\/doi.org\/10.1111\/bjh.12659","journal-title":"Br J Haematol"},{"issue":"4","key":"3042_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"9","key":"3042_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"issue":"16","key":"3042_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"3042_CR5","unstructured":"Japanese Society of Hematology (2023) Practical guidelines for hematological malignancies. http:\/\/www.jshem.or.jp\/gui-hemali\/table.html. Accessed 03 Feb 2026"},{"issue":"1","key":"3042_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-025-03997-z","volume":"122","author":"K Ohmachi","year":"2025","unstructured":"Ohmachi K (2025) JSH practical guidelines for hematological malignancies, 2023: II. lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Int J Hematol 122(1):3\u201316. https:\/\/doi.org\/10.1007\/s12185-025-03997-z","journal-title":"Int J Hematol"},{"issue":"2","key":"3042_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ et al (2023) Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 389(2):148\u2013157. https:\/\/doi.org\/10.1056\/NEJMoa2301665","journal-title":"N Engl J Med"},{"issue":"18","key":"3042_CR8","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH (2022) CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood 139(18):2737\u20132746. https:\/\/doi.org\/10.1182\/blood.2022015789","journal-title":"Blood"},{"issue":"287","key":"3042_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802","volume":"7","author":"LL Sun","year":"2015","unstructured":"Sun LL, Ellerman D, Mathieu M et al (2015) Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 7(287):287ra270. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4802","journal-title":"Sci Transl Med"},{"key":"3042_CR10","unstructured":"U.S. Food and Drug Administration (2022) Prescribing information: Lunsumio\u2122 (mosunetuzumab-axgb) injection, of intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf. Accessed 18 June 2025"},{"issue":"4","key":"3042_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"key":"3042_CR12","unstructured":"U.S. Food and Drug Administration (2023) POLIVY\u00ae Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761121s008lbl.pdf. Accessed 10 Mar 2025"},{"issue":"5","key":"3042_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70169","volume":"6","author":"N Kawasaki","year":"2025","unstructured":"Kawasaki N, Shu S, Tomita M et al (2025) Polatuzumab vedotin induced CD20 upregulation contributes to the efficacy of mosunetuzumab in combination with polatuzumab vedotin in diffuse large B-cell lymphoma preclinical models. EJHaem 6(5):e70169. https:\/\/doi.org\/10.1002\/jha2.70169","journal-title":"EJHaem"},{"issue":"17","key":"3042_CR14","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","volume":"7","author":"NL Bartlett","year":"2023","unstructured":"Bartlett NL, Assouline S, Giri P et al (2023) Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 7(17):4926\u20134935. https:\/\/doi.org\/10.1182\/bloodadvances.2022009260","journal-title":"Blood Adv"},{"issue":"2","key":"3042_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155\u2013165. https:\/\/doi.org\/10.1200\/jco.19.00172","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"3042_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2024-194581","volume":"144","author":"JC Chavez","year":"2024","unstructured":"Chavez JC, Olszewski AJ, Bastos-Oreiro M et al (2024) A randomized phase II study of mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL). Blood 144(Supplement 1):989\u2013989. https:\/\/doi.org\/10.1182\/blood-2024-194581","journal-title":"Blood"},{"key":"3042_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41591-023-02726-5","volume":"30","author":"EL Budde","year":"2024","unstructured":"Budde EL, Olszewski AJ, Assouline S et al (2024) Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial. Nat Med 30:220\u2013239. https:\/\/doi.org\/10.1038\/s41591-023-02726-5","journal-title":"Nat Med"},{"issue":"36","key":"3042_CR18","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1200\/JCO-25-01957","volume":"43","author":"LE Budde","year":"2025","unstructured":"Budde LE, Zhang H, Kim WS et al (2025) Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. J Clin Oncol 43(36):3799\u20133811. https:\/\/doi.org\/10.1200\/JCO-25-01957","journal-title":"J Clin Oncol"},{"issue":"3","key":"3042_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E et al (2013) ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24(3):561\u2013576. https:\/\/doi.org\/10.1093\/annonc\/mds517","journal-title":"Ann Oncol"},{"issue":"27","key":"3042_CR20","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"4","key":"3042_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"3042_CR22","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","volume":"25","author":"H Goto","year":"2020","unstructured":"Goto H, Makita S, Kato K et al (2020) Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Int J Clin Oncol 25(9):1736\u20131743. https:\/\/doi.org\/10.1007\/s10147-020-01699-6","journal-title":"Int J Clin Oncol"},{"issue":"24","key":"3042_CR23","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/cam4.4820","volume":"11","author":"S Makita","year":"2022","unstructured":"Makita S, Yamamoto G, Maruyama D et al (2022) Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med 11(24):4889\u20134899. https:\/\/doi.org\/10.1002\/cam4.4820","journal-title":"Cancer Med"},{"issue":"1","key":"3042_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10147-021-02033-4","volume":"27","author":"K Kato","year":"2022","unstructured":"Kato K, Makita S, Goto H et al (2022) Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol 27(1):213\u2013223","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"3042_CR25","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s10147-025-02788-0","volume":"30","author":"K Izutsu","year":"2025","unstructured":"Izutsu K, Kumode T, Yuda J et al (2025) Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. Int J Clin Oncol 30(8):1631\u20131640. https:\/\/doi.org\/10.1007\/s10147-025-02788-0","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"3042_CR26","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H et al (2024) Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38(12):2653\u20132662. https:\/\/doi.org\/10.1038\/s41375-024-02410-8","journal-title":"Leukemia"},{"issue":"7","key":"3042_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-lne therapy for large B-cell lymphoma. N Engl J Med 386(7):640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"issue":"10254","key":"3042_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"1","key":"3042_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03042-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03042-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:41Z","timestamp":1784997341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03042-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03042-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M. reports honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai Pharmaceutical Co., Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis and Pfizer, and research funding from Ono, Janssen, Eisai, Chugai Pharmaceutical Co., Ltd, Kyowa Kirin, MSD, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, Bristol Myers Squibb, Genmab, Novartis Otsuka, Taiho, Pfizer and Astellas. H.G. reports honoraria from Chugai Pharmaceutical Co., Ltd, Kyowa Kirin, AbbVie, Kite\/Gilead, Novartis and Bristol Myers Squibb, and research funding from AbbVie, Bristol Myers Squibb, Kyowa Kirin, Kite\/Gilead and Sanofi. T.K. reports honoraria from Chugai Pharmaceutical Co., Ltd, AstraZeneca, Ono, BeOne, AbbVie, Genmab and Janssen. K.A. has no conflicts of interest to report. N.F. reports honoraria from Bristol Myers Squibb and Chugai Pharmaceutical Co., Ltd, and research funding from AbbVie, Incyte, Chordia Therapeutics, GenMab, Takeda, Chugai Pharmaceutical Co., Ltd, LOXO oncology, Kaiwa and Ono. J.R.W. reports honoraria from AbbVie\/GenMab, AstraZeneca, Nurix, Janssen, Morphosys\/Incyte, ADC Therapeutics, Bristol Myers Squibb, Genentech, Inc., Kite\/Gilead, Allogene, Novartis, Regeneron and Pfizer, and research funding from AstraZeneca, Nurix, Janssen, Morphosys\/Incyte, ADC Therapeutics, Bristol Myers Squibb, Genentech, Inc., Kite\/Gilead, Allogene and Novartis. W.S.K. reports research funding from Sanofi, BeiGene, Boryung, F.\u00a0Hoffmann-La Roche Ltd, Kyowa Kirin and Donga. C.M. is an employee of Chugai Pharmaceutical Co., Ltd and reports stock ownership from Chugai Pharmaceutical Co., Ltd. T.I. is an employee of Chugai Pharmaceutical Co., Ltd. K.K. reports honoraria from Novartis, Chugai Pharmaceutical Co., Ltd and AbbVie, and research funding from Chugai Pharmaceutical Co., Ltd, Takeda, Kyowa Kirin, AbbVie, Novartis, Eisai, Janssen, Ono, Meiji, Daiichi Sankyo, MSD, Bristol Myers Squibb, Gilead Sciences, Astellas, Nippon-Shinyaku.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki, the Act on the Protection of Personal Information, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol was reviewed and approved by the centralized ethics committee (Clinical Research Network Fukuoka Ethics committee).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for participation in the study. Patients were able to withdraw from the study at any time.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}